Current position

Ray Dalio’s Johnson & Johnson (JNJ) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Bridgewater Associates, LPVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ2 2006Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares4.71MHighest verified quarter-end share count
Quarters reported50Verified quarters with shares above zero
What happened?

Bridgewater Associates, LP first reported Johnson & Johnson in Q2 2006. After an earlier exit, the position later appeared again in a verified filing. The reported position was increased and reduced across later filings. Bridgewater Associates, LP currently reports 669.14K shares. The latest verified filing showed: Sold 4.0% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 4.0% of the position−27.75K shares · 669.14K shares remained
Filing context

Quarter-end price $253.97 · Estimated holding basis $154.02

Q1 2026
Sold 47.0% of the position−617.07K shares · 696.88K shares remained
Filing context

Quarter-end price $244.44 · Estimated holding basis $154.02

Q4 2025
Sold 23.4% of the position−401.82K shares · 1.31M shares remained
Filing context

Quarter-end price $206.95 · Estimated holding basis $154.02

Q3 2025
Sold 24.8% of the position−566.76K shares · 1.72M shares remained
Filing context

Quarter-end price $185.42 · Estimated holding basis $154.02

Q2 2025
Bought 667.8% more+1.99M shares · 2.28M shares reported after the change
Filing context

Quarter-end price $152.75 · Estimated holding basis $154.02

Q1 2025
Sold 44.7% of the position−240.65K shares · 297.29K shares remained
Filing context

Quarter-end price $165.84 · Estimated holding basis $162.53

Portfolio importance

How important is Johnson & Johnson in Bridgewater Associates, LP’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.7%Q2 2026
Current rank#16of 997 reported positions
Peak portfolio weight3.9%Q3 2022
Best historical rank#2Q1 2007
At peak importanceQ3 2022
JNJ
3.9%
Largest holding
4.2%
Cross-investor discovery

Who else owns Johnson & Johnson?

Also reported by 4 other tracked investors in their latest verified filings.

Joel GreenblattGotham Asset Management
JNJ0.1% of reported portfolio
George SorosSoros Fund Management
JNJ0.1% of reported portfolio
Christopher BloomstranSemper Augustus Investments Group LLC
JNJ0.0% of reported portfolio
Explore Johnson & Johnson across all tracked investors →
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$269.992026-09-18

Market context only; not an investor transaction price.

Latest filing quarter-end price$253.97Q2 2026

Derived from validated reported value and shares where supported.

Estimated holding basis$154.02Historical reference — not actual purchase price

Calculated from supported filing history.

Latest verified investor filingQ2 2026 · filed 2026-08-14
Open SEC filing ↗

View Johnson & Johnson stock page →

This tracker follows Bridgewater Associates, LP’s Form 13F disclosures, not Ray Dalio’s personal brokerage account. Form 13F reports quarter-end positions later and does not reveal exact trade dates or execution prices.